Ginkgo Bioworks Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M |
| Research and development | $243.8M | $424.1M | $580.6M | $1.1B | $1.1B |
| Operating expenses | $485.4M | $786.8M | $1.1B | $2.7B | $2.1B |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.2B | -$1.8B |
| Interest expense | $0 | $94,000 | $93,000 | $106,000 | $2.4M |
| Pretax income | -$313.6M | -$547.5M | -$892.9M | -$2.1B | -$1.8B |
| Income tax expense | -$837,000 | -$479,000 | -$71,000 | -$15.0M | -$1.5M |
| Net income | -$312.8M | -$547.0M | -$892.9M | -$2.1B | -$1.8B |
| Balance Sheet | |||||
| Cash and equivalents | $167.2M | $561.6M | $944.1M | $1.3B | $1.6B |
| Current assets | $471.8M | $602.7M | $1.0B | $1.5B | $1.7B |
| Total assets | $1.1B | $1.4B | $1.7B | $2.5B | $2.1B |
| Current liabilities | $96.0M | $107.3M | $163.9M | $173.0M | $134.8M |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M |
| Stockholders' equity | $508.6M | $716.1M | $1.1B | $1.7B | $1.5B |
| Cash Flow Statement | |||||
| Cash from operations | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M |
| Depreciation and amortization | $40.3M | $45.0M | $54.8M | $36.9M | $26.9M |
| Stock-based compensation | $81.5M | $112.3M | $229.9M | $1.9B | $1.6B |
| Capital expenditure | $7.7M | $62.5M | $40.8M | $52.3M | $56.5M |
| Free cash flow | -$178.7M | -$382.1M | -$336.3M | -$304.5M | -$310.3M |
| Share repurchases | — | — | $0 | $0 | $25.0M |
| Impairments | $0 | $4.8M | $0 | $0 | $0 |
Shares outstanding 65.3M · Free float 87.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.